DOI: 10.1002/cmdc.201500142
Communications
Antitumor Activity of Ionic Liquids Based on Ampicillin
Ricardo Ferraz,[a, b] Jo¼o Costa-Rodrigues,*[c] Maria H. Fernandes,[c] Miguel M. Santos,[a]
Isabel M. Marrucho,[d] Luís Paulo N. Rebelo,[d] Cristina PrudÞncio,[b, e] Jo¼o Paulo Noronha,[a]
[a]
[a]
ˇ
Zeljko Petrovski,* and Luís C. Branco*
Significant antiproliferative effects against various tumor cell
lines were observed with novel ampicillin salts as ionic liquids.
The combination of anionic ampicillin with appropriate ammo-
nium, imidazolium, phosphonium, and pyridinium cations
yielded active pharmaceutical ingredient ionic liquids (API-ILs)
that show potent antiproliferative activities against five differ-
ent human cancer cell lines: T47D (breast), PC3 (prostate),
HepG2 (liver), MG63 (osteosarcoma), and RKO (colon). Some
API-ILs showed IC50 values between 5 and 42 nm, activities that
stand in dramatic contrast to the negligible cytotoxic activity
level shown by the ampicillin sodium salt. Moreover, very low
cytotoxicity against two primary cell lines—skin (SF) and gingi-
val fibroblasts (GF)—indicates that the majority of these API-ILs
are nontoxic to normal human cell lines. The most promising
combination of antitumor activity and low toxicity toward
healthy cells was observed for the 1-hydroxyethyl-3-methylimi-
dazolium–ampicillin pair ([C2OHMIM][Amp]), making this the
most suitable lead API-IL for future studies.
or potassium form, have been developed to improve aqueous
solubility. Ionic liquids (ILs) are a peculiar class of organic salts
with melting points below 1008C which have been the focus
of increasing interest in the scientific community and industry;
the large number of potential cation–anion combinations
allows a variety of tunable interactions and applications.[1] One
of the most promising applications of ILs is in the so-called
third generation of ILs, that is, their arrangement with APIs to
generate API-ILs.[2–6] Successful buffer-controlled procedures for
the preparation of API-ILs containing the anion of ampicillin (a
well-known antibiotic) combined with members of four organ-
ic cation classes (ammonium, imidazolium, phosphonium, and
pyridinium) have been reported.[7–9] These API-IL combinations
can be an innovative solution to the polymorphic behavior of
certain drugs, and can also improve water solubility, permeabil-
ity, and therefore bioavailability. The appropriate arrangement
of a biocompatible anion or cation with a specific drug can be
relevant in modifying the corresponding biopharmaceutical
drug classification system (BCS)[2,4,10–12] as well as their drug for-
mulation process.
Researchers in the pharmaceutical industry are currently facing
a series of challenges in the discovery of innovative and effec-
tive drugs and their subsequent therapeutic applications. Most
active pharmaceutical ingredients (APIs) are available in solid
form, a state that frequently suffers from polymorphic conver-
sion, low solubility, and a variety of other factors that affect
the final bioavailability. Various pharmaceutical salts, in sodium
The important question regarding the toxicity of the API
counter-ion in ILs has been the major cause behind the de-
layed entry of ILs into the wider biosciences field.[5,13] Toxicities
toward microorganisms and eukaryotic cell cultures cover the
entire range of biocidal potencies, from rather inactive molecu-
lar solvents that are biocompatible, up to high concentrations
in aqueous solutions for pharmaceutical applications,[2,4,12] and
even as potential in vitro anticancer agents.[8,10] Antimicrobial
activities against Escherichia coli (susceptible and resistant),
Klebsiella pneumoniae, Staphylococcus aureus, and Enterococcus
faecium have been reported for some ampicillin organic salts
in comparison with sodium ampicillin ([Na][Amp]).[9,14] Conse-
quently, the development of novel anticancer drugs that are
less toxic than currently available chemotherapeutic treat-
ments can also be pursued with ionic liquids.[3,4,12] Herein we
describe the antiproliferative effects of several previously syn-
thesized ampicillin ILs (Figure 1) against various tumor cell
lines.
ˇ
[a] Dr. R. Ferraz, Dr. M. M. Santos, Prof. J. P. Noronha, Dr. Z. Petrovski,
Dr. L. C. Branco
Departamento de Química, REQUIMTE-CQFB, Faculdade de CiÞncias e Tec-
nologia da Universidade Nova de Lisboa, 2829-516 Caparica (Portugal)
[b] Dr. R. Ferraz, Prof. C. PrudÞncio
CiÞncias Químicas e das BiomolØculas, Escola Superior de Tecnologia da
Safflde do Porto do Instituto PolitØcnico do Porto, Rua Valente Perfeito 322,
4400-330 Vila Nova de Gaia (Portugal)
[c] Prof. J. Costa-Rodrigues, Prof. M. H. Fernandes
Laboratório de Farmacologia e Biocompatibilidade Celular, Faculdade de
Medicina Dentµria, Universidade do Porto, Rua Dr. Manuel Pereira da Silva,
4200-393 Porto (Portugal)
Table 1 summarizes the antitumor activities (IC50 and LD50) of
the ampicillin-anion-based ILs against two primary human cell
types: skin (SF) and gingival fibroblasts (GF). [Na][Amp] was
used as control, and as is evident from the data listed in
Table 1, it is one of the least toxic. The IC50 value was not de-
tected in the concentration range used against SF, and the IC50
value toward GF was 109.1 mm. In comparing the other synthe-
sized compounds with [Na][Amp], the most toxic toward the
healthy human cell lines are [P6,6,6,14][Amp] and [C16Pyr][Amp]
(lowest IC50 values). Ammonium-based ILs [TEA][Amp] and
[d] Dr. I. M. Marrucho, Prof. L. P. N. Rebelo
Instituto de Tecnologia Química e Biológica, ITQB, Universidade Nova de
Lisboa, Av. da Repfflblica Estażo Agronómica Nacional, 2780-157 Oeiras
(Portugal)
[e] Prof. C. PrudÞncio
Centro de Farmacologia e Biopatologia Química (U38-FCT), Faculdade de
Medicina da Universidade do Porto (FMUP) (Portugal)
Supporting information for this article is available on the WWW under
ChemMedChem 2015, 10, 1480 – 1483
1480
ꢀ 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim